1. Q3A (R2): impurities in new drug substances;ICH,2006
2. M7 guideline: assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk;ICH,2017
3. Guidance for industry: S2 (R1) guideline: genotoxicity testing and data interpretation for pharmaceuticals intended for human use;USFDA,2012
4. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening;Bobadilla;Hum Mutat,2002
5. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR;Wainwright;N Engl J Med,2015